CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Sales	$ 53,580,523	$ 50,466,339	$ 107,612,255	$ 97,693,800
Cost of sales	16,122,262	16,130,889	32,739,020	31,846,616
Gross profit	37,458,261	34,335,450	74,873,235	65,847,184
Operating expenses
Selling expenses	2,441,727	4,165,242	4,278,120	8,991,349
General and administrative expenses	8,866,071	7,932,372	17,553,168	15,078,166
Research and development expenses	835,150	929,489	1,748,242	1,640,077
Income from operations	25,315,313	21,308,347	51,293,705	40,137,592
Other income/ (expenses)
Equity in income of an equity method investee	610,997	451,891	739,945	1,474,303
Change in fair value of derivative liabilities	0	559,758	0	1,769,140
Interest expense	(198,739)	(157,635)	(434,913)	(766,198)
Interest income	995,757	765,717	1,643,819	1,309,112
Other expenses, net	0	(1,797)	0	(102,786)
Total other income, net	1,408,015	1,617,934	1,948,851	3,683,571
Earnings before income tax expense	26,723,328	22,926,281	53,242,556	43,821,163
Income tax expense	3,745,649	3,333,616	8,352,551	6,510,331
Net income	22,977,679	19,592,665	44,890,005	37,310,832
Less: Net income attributable to noncontrolling interest	6,815,753	6,753,894	13,812,219	11,514,755
Net income attributable to China Biologic Products, Inc.	16,161,926	12,838,771	31,077,786	25,796,077
Net income per share of common stock:
Basic	$ 0.60	$ 0.50	$ 1.15	$ 1.00
Diluted	$ 0.57	$ 0.46	$ 1.11	$ 0.90
Weighted average shares used in computation:
Basic	26,880,459	25,875,164	26,833,262	25,738,145
Diluted	28,067,303	26,627,160	27,967,080	26,581,824
Net income	22,977,679	19,592,665	44,890,005	37,310,832
Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes	4,428,715	136,178	5,825,256	1,313,135
Comprehensive income	27,406,394	19,728,843	50,715,261	38,623,967
Less: Comprehensive income attributable to noncontrolling interest	7,723,790	6,750,933	14,882,947	11,766,768
Comprehensive income attributable to China Biologic Products, Inc.	$ 19,682,604	$ 12,977,910	$ 35,832,314	$ 26,857,199